Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Tirabrutinib Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Tirabrutinib Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ravidasvir Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Ravidasvir Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Halobetasol Propionate/Tazarotene Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Halobetasol Propionate/Tazarotene: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Gefapixant Citrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Gefapixant Citrate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Imlifidase Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Imlifidase: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Naxitamab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Naxitamab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Clascoterone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Clascoterone: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Anamorelin Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Anamorelin Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Evogliptin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Evogliptin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Tirbanibulin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Tirbanibulin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Remogliflozin etabonate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Remogliflozin etabonate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Peficitinib Hydrobromide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Peficitinib Hydrobromide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.